良性前列腺增生和前列腺癌组织中雄激素受体的表达

目的　探讨雄激素受体 (AR)与良性前列腺增生 (BPH)和前列腺癌 (PCa)的关系。　方法　应用免疫组织化学技术检测 4 0例BPH、4 0例PCa患者及 2 0例正常前列腺组织 (正常对照组 )AR的表达。　结果　BPH组、PCa组、正常对照组AR表达的阳性率分别为 98%、5 3%、75 % ,相互比较差异均有显著性 (P <0 0 5 )。高分化癌、中分化癌、低分化癌的AR表达的阳性率分别为 6 7%、5 6 %、30 % ,高、中分化癌的AR表达的阳性率比低分化癌高 (P <0 0 5 )。早期前列腺癌的AR表达阳性率 (6 9% )比晚期前列腺癌 (4 2 % )高 (P <0 0 5 )。　结论　BPH组织中AR的表达高于正常前列腺组织 ,AR在BPH的发生、发展中起着重要作用 ;PCa组织中AR的表达低于正常前列腺组织。AR的表达与肿瘤分级、分期相关。     

凋亡抑制基因生存素在胃癌组织中的表达及意义

目的　研究凋亡抑制基因生存素在胃癌组织的表达及其与临床病理指标的关系 ,以探讨其在胃癌发生、发展中的作用。方法　应用免疫组化Envision法检测生存素在 6 5例胃癌中的表达情况 ,分析它们与胃癌临床病理指标的关系。结果　 (1) 6 5例胃癌组织中生存素总的阳性率为 5 3.85 %(35 / 6 5 ) ;2 0例胃良性溃疡无一例生存素表达阳性。 (2 )Ⅰ、Ⅱ、Ⅲ、Ⅳ期胃癌组织中生存素阳性率分别为 2 / 8例、2 6 .32 % (5 / 19)、74 .0 7% (2 0 / 2 7)、72 .73% (8/ 11) ,Ⅰ期 +Ⅱ期 /Ⅲ期 +Ⅳ期 =2 5 .93% (7/ 2 7)∶73.6 8% (2 8/ 38) ,差异有显著性 (P <0 .0 1)。 (3)淋巴结转移阳性 (N1)的胃癌组织中生存素阳性表达率为 6 2 .86 % (2 2 / 35 ) ,无淋巴结转移 (N0 )为 4 3.33% (13/ 30 ) ,差异有显著性 (P <0 .0 5 )。 (4)有远处转移 (M1)的胃癌组织中生存素阳性表达率为 7/ 9例 ,无远处转移 (M0 )的阳性率为 5 0 .0 0 % (2 8/ 5 6 ) ,差异有显著性 (P >0 .0 5 )。 (5 )高分化、中分化、低分化腺癌的胃癌组织中生存素的阳性率分别为 4 0 .0 0 %(8/ 12 )、5 5 .5 6 % (10 / 18)、6 2 .96 % (17/ 2 7) ,呈逐渐增高的趋势 ,但各组间两两比较均差异无显著性 (P >0 .0 5 )。结论　生存素基因在胃癌的发生发展中起重要作     

食管鳞癌中TGF-β1与临床病理因素关系意义的研究

目的　研究食管鳞癌中TGF β1的表达 ,及它在食管鳞癌细胞的增殖、侵袭、转移中的作用。方法　运用免疫组织化学方法研究TGF β1蛋白表达情况 ,显微镜下计数阳性细胞指数 (LI) ,并进行统计分析。结果　①正常食管黏膜阳性率为 2 0 % (2 / 10 ) ,食管鳞癌组织为 62 % (3 1/ 50 ) ,两者差异有显著性 (χ2 =5.93 94,P =0 .0 15) ;LI后者高于前者 (t=2 .717,P =0 .0 0 9) ,正常食管黏膜阳性 2例 ,均为弱阳性 (LI <2 5% )。②TGF β1在食管鳞癌组织中的表达与年龄、性别无明显关系 (P >0 .0 5) ,不同分化级别中两者表达亦无差异 (P >0 .0 5)。有淋巴结转移组TGF β1水平高于无淋巴结转移组 ,差异有显著性 ,P =0 .0 0 3。食管外膜浸润组TGF β1显著高于未受浸润组 ,P =0 .0 0 1,临床分期Ⅰ Ⅱ与Ⅲ Ⅳ期TGF β1表达水平差异有显著性 ,P =0 .0 0 0。结论　①食管鳞癌中存在TGF β1的高表达 ,表达水平与淋巴结转移、浸润侵袭、临床分期等有关 ,其检测有辅助诊断作用 ,且有利于判断肿瘤转移、浸润和后继治疗 ;②表达水平与组织分级无关 ,提示TGF β1在促进肿瘤局部侵袭转移中的重大作用 ,有助于理解临床上一些肿瘤生物学行为与组织分级不符的现象     

小肠三叶肽在大肠癌中的表达及其意义

目的　探讨小肠三叶肽 (ITF)与大肠癌的发生、进展及预后的关系。方法　收集手术切除的大肠癌标本 ,同时取距癌灶 5cm以外的癌旁组织及 10cm以外的正常组织。用原位杂交法检测癌组织、癌旁组织及正常组织中ITFmRNA ,同时结合临床病理资料进行分析。结果　癌组织、癌旁组织及正常组织均有不同程度的ITFmRNA表达 ,三组间ITFmRNA表达比较 ,差异无显著性 (P >0 .0 5 )。在结肠癌组织中 ,Dukes分期较高 (B、C、D期 )组的ITFmRNA表达 (0 .3 14±0 .119)明显低于Dukes分期较低 (A期 )组的表达 (0 .45 3± 0 .10 2 ) ,两者比较差异有显著性 (P <0 .0 5 )。但在癌旁和正常组织中 ,ITFmRNA的表达在不同Dukes分期组中的表达差异无显著性 (P>0 .0 5 )。不同分化程度组间ITFmRNA的表达差异亦无显著性 (P >0 .0 5 )。ITFmRNA的表达与是否有淋巴结转移及远处转移无密切相关 (P >0 .0 5 )。结论　ITFmRNA不仅表达于正常结肠粘膜 ,亦表达于癌旁和癌组织。ITF的表达在Dukes分期较高组低于分期较低组 ,且与分化程度有潜在的正相关 ,提示ITF可能与肿瘤的进展呈负相关     

多药耐药基因1 P-糖蛋白在肺癌中的表达及其临床意义

采用 SABC免疫组化法对 10 6例肺癌组织进行多药耐药基因 1P-糖蛋白 (以下简称 P- gp)表达检测 ,并进行相关临床因素分析。10 6例标本中 ,P- gp阳性率 5 6 .6 % ,低分化鳞癌、腺癌与中、高分化型 P- gp阳性率分别为4 2 .9%及 78.6 % ,差别显著 (P<0 .0 5 ) ;P- gp阳性表达的鳞癌 (5 5 .6 % )与腺癌 (86 .7% )、小细胞未分化癌 (SCL C)(18.1% )与非小细胞未分化癌 (NSCL C) (6 6 .7% )之间均有显著性差异 (P均 <0 .0 5 ) ;TNM分期 ～ 期 P- gp阳性率分别为 5 5 .6 %、5 2 .6 %、5 6 % ,统计学无差异 (P>0 .0 5 ) ;有淋巴结转移的 P- gp阳性表达为 5 9% ,无淋巴结者为 5 7.2 % ,二者无显著差异 (P>0 .0 5 )。32例接受化疗 P- gp阳性者的有效率为 2 2 .2 % ,阴性者为 5 7.1% ,有显著性差异 (P<0 .0 5 )。认为 P- gp可作为预示化疗敏感性的分子标记物 ,是评价化疗耐药性和预后的可靠指标     

外周血液CEAmRNA基因表达与食管癌微转移关系的研究

目的探讨靶基因CEAmRNA在食管癌患者外周血中的表达及与肿瘤微转移的关系.方法应用巢式-反转录聚合酶链反应(Nested-RT-PCR)检测50例无远处转移、10例有远处转移的食管癌患者,10例食管良性病变和10例健康成人外周血中癌胚抗原CEAmRNA基因的表达.结果食管癌良性病变者和健康成人的外周血中均未检测出CEAmRNA阳性细胞.50例无远处转移、10例有远处转移的食管癌患者外周血中CEAmRNA阳性率分别为30.2%(16/50)、80.0%(8/10),P＜0.01;食管癌Ⅳ期与Ⅱa、Ⅱb、Ⅲ期者阳性率比较差异有显著性(P均＜0.01),而其他各期之间阳性率比较差异无显著性(P＞0.05);不同程度病理分化者间阳性率比较差异无显著性(P＞0.05).结论食管癌患者临床早期已有癌细胞微转移.应用Nested-RT-PCR检测外周血中CEAmRNA靶基因有助于早期诊断.     

急性白血病患者血管内皮生长因子及其受体表达的临床意义

目的 :探讨血管内皮生长因子 (VEGF)及其受体 (VEGFR)在成人急性白血病 (AL)中的表达、对临床疗效和预后的影响以及与多药耐药的关系。方法 :采用逆转录 聚合酶链反应 (RT PCR)方法检测 6 4例成人AL患者VEGF、VEGFR 1、VEGFR 2、mdr 1mRNA表达水平。结果 :VEGF基因在AL组中表达的平均水平和阳性率均高于正常对照组 (P <0 .0 5 )。其中急性粒细胞白血病 (AML)组广泛表达 ,明显高于正常对照组 (P <0 .0 5 ) ,而急性淋巴细胞白血症 (ALL)组的表达与正常对照组相比差异无显著性意义 (P >0 .0 5 )。AL组VEG FR 1表达阳性率高于正常对照组 (P <0 .0 5 ) ;VEGFR 2表达阳性率与正常对照组相比无显著性意义 (P >0 .0 5 )。VEGF表达水平在临床耐药组高于临床敏感组 (P <0 .0 5 ) ,是影响缓解率和生存期的危险因素。VEGF与mdr 1表达无相关关系。结论 :VEGF及VEGFR 1基因在成人AL患者中有异常表达 ,是影响成人AL患者临床疗效和预后的因素之一。     

大肠癌组织中端粒酶催化亚单位的表达及临床意义

目的:探讨端粒酶催化亚单位(hTERT)在大肠癌患者中的表达情况及与及临床病理类型、淋巴结转移和复发之间的关系.方法:免疫组化法测定大肠癌组织(n=45)、腺瘤组织(n=16)及正常大肠黏膜(n=10)hTERT表达情况,并将hTERT表达情况与大肠癌临床病理类型、淋巴结转移和肿瘤复发之间的关系进行总结.结果:大肠癌患者癌组织中的hTERT阳性率为77.8%,显著高于腺瘤组(2/16)和正常大肠黏膜组(0/10),有显著性差异(P＜0.05).hTERT表达强度与淋巴结转移呈高度相关性(r=5.2,P＜0.05).大肠癌复发转移平均时间阳性组为34±5 mo,阴性组为20±6 mo,差异有显著性(P＜0.05).结论:hTERT在大肠癌组织中有高表达,hTERT免疫组化检测结果可以作为大肠癌早期诊断和淋巴结转移的一个重要参考指标.     

PR、ER在食管癌组织中的表达及与预后的关系

目的探讨孕激素受体(PR)、雌激素受体(ER)表达在食管癌发病及预后中的作用,为临床预测食管癌的转归和内分泌治疗提供依据。方法采用免疫组织化学染色法,以PR、ER多克隆抗体检测PR、ER在食管癌组织中的表达情况,同时分析其与临床病理参数的关系。结果①食管癌组织中PR和ER表达阳性率分别为21.97%(30/137)、23.35%(32/137),PR、ER表达有极显著相关性。②生存时间≥10 a者PR、ER表达阳性率均显著高于生存时间<2 a者(P<0.05),有淋巴结转移者PR、ER表达阳性率与无淋巴结转移者均无显著差异。③女性PR/ER阳性率明显高于男性(P<0.05),但其10年生存率无显著差异;存活10 a以上女性的PR/ER阳性率显著高于2 a内死亡者(P<0.05),而男性则无显著差异。结论 PR、ER表达在食管癌发病及预后方面均有高度协同作用,此为食管癌的内分泌治疗及预后判定提供了病理学依据。     

CD44s、CD44v6、CD44v9在骨肉瘤、骨巨细胞瘤及骨软骨瘤标本的表达及临床意义

目的探究变异体CD44s、CD44v6及CD44v9与骨肉瘤分化、转移及恶性程度的关系。方法通过q PCR技术检测10例骨肉瘤、8例骨巨细胞瘤、5例骨软骨瘤标本中变异体CD44s、CD44v6及CD44v9的表达水平,应用统计学方法进行数据处理,同时结合患者临床资料和病理资料进行相关性分析。结果(1)CD44s、CD44v6在骨肉瘤和骨巨细胞瘤中的表达明显高于骨软骨瘤(均P0.05),但在骨肉瘤和骨巨细胞瘤之间的表达无显著差异(均P0.05)。(2)CD44v9在骨软骨瘤中无表达,在骨肉瘤和骨巨细胞瘤之间的表达无显著差异(P0.05)。(2)CD44v9在低分化骨肉瘤表达高于高分化骨肉瘤(P0.05),在转移性骨肉瘤表达高于非转移性骨肉瘤(P0.05),而CD44s和CD44v6与骨肉瘤分化和转移无显著相关性(P0.05)。结论 CD44s、CD44v6及CD44v9在不同骨肿瘤之间表达有差异。CD44s、CD44v6及CD44v9三者当中只有CD44v9的表达与骨肉瘤的分化和转移有相关性,并且分化和转移关系密切。CD44v9可作为判断骨肉瘤恶性程度的一个指标。     

High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma

Purpose

Analyze protein and gene expression of mGluRs (mGluR1, mGluR5, mGluR4) in osteosarcoma tissues and discuss the relation between expression level and clinical characteristics of osteosarcoma, and study the clinical significance.

Methods

Detect protein and mRNA expression level of mGluRs (mGluR1, mGluR5, mGluR4) in 40 osteosarcoma tissues and the corresponding adjacent normal tissues by Western blot and RT-PCR accordingly. Immunohistochemistry was adopted to detect the expression of mGluRs (mGluR1, mGluR5, mGluR4) in 118 paraffin embedded osteosarcoma tissues and eight normal bone tissues. Then, the correlation between the expression and clinical characteristics of patients was analyzed. Furthermore, survival analysis of osteosarcoma was performed to study the relation between expression level of mGluRs and patient prognosis.

Results

No correlation of mGluR1 and mGluR5 with clinicopathologic characteristics of osteosarcoma was found. Statistical analysis demonstrated that the expression level of mGluR4 shared no significant correlation with gender, age, histologic type and tumor location of patient, but was related to Enneking stage and tumor metastasis (P < 0.05). High mGluR4 expression is more frequently noted in the osteosarcoma tissues with higher Enneking stage and metastasis. The results of Western blot and RT-PCR indicated a significantly increased expression level of mGluR4 gene and protein in osteosarcoma tissues compared with normal tissues. Though higher gene and protein expression of mGluR5 and mGluR1 were also indicated in osteosarcoma tissues compared with normal tissues, no statistical significance was noted for the difference (P > 0.05). According to the survival analysis of 118 osteosarcoma patients, cases in the mGluR4 high-expression group showed inferior disease-free survival rate and poorer overall survival rate.

Conclusion

High expression of mGluR4 in osteosarcoma tissues is related to poor prognosis, thus holding certain reference value for estimating prognosis of osteosarcoma patients.     

KAI1和CD44v6在骨肉瘤中的表达及意义

目的探讨KAI1和CD44v6蛋白在骨肉瘤中的表达及其与临床病理特征及预后的关系。方法应用免疫组织化学SP法,检测87例骨肉瘤组织中KAI1和CD44v6蛋白的表达,用Cox风险回归模型评价骨肉瘤患者预后独立因素。结果KAI1蛋白与肿瘤的分化程度、远处转移相关,而CD44v6仅与远处转移相关。骨肉瘤KAI1和CD44v6的表达无相关性。Cox模型分析显示影响骨肉瘤患者预后因素是KAI1表达、远处转移和Enneking外科分期。结论KAI1和CD44v6的异常表达参与了骨肉瘤的转移过程,KAI1表达、远处转移、Enneking外科分期是预测骨肉瘤患者预后的独立因素。     

骨肉瘤组织中N-cadherin、Ezrin蛋白测定及临床意义

目的探讨N-钙黏附素（N-cadherin）、埃兹蛋白（Ezrin）表达在骨肉瘤发生中的作用及与预后的相关性。方法采用免疫组化法检测54例骨肉瘤、11例骨样骨瘤、7例骨母细胞瘤及8例反应性新生骨组织中N-cadherin和Ezrin表达情况,分析两指标间及与骨肉瘤临床病理参数的关系。结果骨肉瘤、骨样骨瘤、骨母细胞瘤、反应性新生骨组织N-cadherin阳性表达率分别为35.19%、63.64%、71.43%、75.00%,Ezrin阳性表达率分别为57.41%、9.09%、14.29%、0.00%,骨肉瘤N-cadherin阳性表达率低于其余三种组织、Ezrin阳性表达率高于其余三种组织,P均〈0.05。二者的表达与骨肉瘤肺转移及2 a内死亡相关,二者表达呈负相关。结论N-cadherin和Ezrin蛋白在骨肉瘤中的表达与转移及预后密切相关。     

Livin and Bcl-2 expression in high-grade osteosarcoma

Aims The evaluation of prognosis in patients with osteosarcoma is limited to clinical parameters. Although numerous molecular markers have been studied, none are currently in routine clinical use. The aim of this study was to determine if Livin and Bcl-2, acting as antiapoptotic proteins through different mechanisms, are expressed in osteosarcoma, and whether they can be used as prognostic markers in human osteosarcoma. Methods Tumor specimens of 29 patients with high-grade central osteosarcoma, with complete clinical follow-up for a minimum of 5 years, were studied. The localization and distribution of Livin and Bcl-2 were investigated using immunohistochemistry. Results were correlated with the histological response to chemotherapy, 5-year disease-free and 5-year overall survival. Results Bcl-2 was expressed only in the cytoplasm of 16/29 cases and there was no statistically significant correlation between expression and any of the studied parameters. Livin was detected in 17/29 cases, in the cytoplasm of all 17 and in the nucleus of only 3 cases. Nuclear expression was significantly correlated with a decreased overall survival (P < 0.0002) compared with those patients without nuclear expression. Conclusions The results of this study indicate that Bc1-2 and Livin are highly expressed in osteosarcoma cells and that possibly, the evaluation of nuclear Livin expression might be a useful prognostic marker in osteosarcoma.     

乳腺癌患者术前雌、孕激素受体的表达及意义

术前对68例乳腺癌患者行细针穿刺(FNA)涂片,用免疫细胞化学(ICA)检测(ABC法)雌激素受体(ER)、孕激素受体(PR)在涂片上的表达;同时应用免疫组化检测相应术后组织切片上ER、PR的表达.结果FNA涂片ICA检测ER阳性率为64.7%(44/68),PR的阳性率为39.7%(27/68);在组织切片上ER的阳性率为58.8%(40/68),PR的阳性率为36.7%(25/68).ER、PR在FNA涂片上的表达与组织切片上的表达无显著差别(P＞0.05).ER在FNA涂片上的表达情况与组织学分级、临床分期呈显著负相关(P＜0.05),腋淋巴结阴性者显著高于腋淋巴结阳性者(P＜0.05),与肿瘤大小无关;PR的表达与组织学分级明显负相关(P＜0.05),与其它指标无关.认为FNA与ICA相结合,对于乳腺癌的早期诊断、指导治疗和判断预后具有重要意义.     

Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients＇ prognosis

AIM: Recent clinical epidemiological studies have demonstrated the preventive effect of non-steroidal antiinflammatory drugs (NSAIDs) against colorectal cancer.The underlying mechanism might be the inhibition of rate-limiting enzyme cyclooxygenase-2 (COX-2) in metabolism of arachidonic acid. The role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients‘ prognosis still remain unclear. This study was to investigate the role of COX-2 expression in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients‘ prognosis.METHODS: A total of 139 colorectal cancers and 19 adenomas surgically treated in School of Oncology, Peking University, from January 1993 to September 2001 were retrospectively studied. COX-2 expression was detected with tissue microarray (TMA) and immunohistochemistry (IHC) procedure. The association between COX-2 expression and clinicopathological features and its influence on patients‘ prognosis were studied.RESULTS: COX-2 expression was strong in colorectal cancer,moderate in adenoma and weak in normal mucosa, which demonstrated statistically significant difference (x^2=46.997,P&lt;0.001). COX-2 expression had no association with clinicopathological features such as gross type,differentiation, invasion depth, vessel emboli and TNM staging. Cox proportional hazards modeling analysis and Log rank test revealed no prognostic role of COX-2 expression in colorectal cancer patients.CONCLUSION: COX-2 may play an important role in the early stage of cardnogenesis, and its expression in colorectal cancer is not associated with dinicopathological features and patients‘ prognosis.     

非小细胞肺癌肿瘤相关巨噬细胞表型检测及临床意义

目的检测非小细胞肺癌（NSCLC）患者肿瘤相关巨噬细胞表型及其分布,探讨NSCLC患者预后与肿瘤相关巨噬细胞各表型的关系。方法收集47例有完整临床病理和随访资料的NSCLC标本,运用免疫组化方法检测CD68、TNF-α、TGF-β1在肿瘤间质及癌旁肺组织巨噬细胞表达,分析其与患者各项临床指标及预后的关系。结果 CD6＋8TNF-α＋M1型巨噬细胞在NSCLC癌组织低于癌旁正常肺组织（P〈0.05）,CD6＋8TNF-β1＋M2型巨噬细胞在NSCLC肿瘤间质高于癌旁正常肺组织（P〈0.05）;M1型及M2型巨噬细胞在肿瘤间质内的数量与临床分期相关（P〈0.05）;Kaplan-Meier生存曲线分析显示患者术后生存率随巨噬细胞TNF-α阳性表达而呈上升趋势,随TGF-β1阳性表达呈现下降趋势。结论 M1型巨噬细胞减少和M2型巨噬细胞增多与NSCLC患者的不良预后有关。     

Long noncoding RNA taurine-up regulated gene 1 for the prognosis of osteosarcoma: A protocol for meta-analysis and bioinformatics analysis

Background:In recent years, a variety of long noncoding RNA (lncRNA) has been confirmed to be involved in the initiation and progression of osteosarcoma. Taurine-up regulated gene 1 (TUG1) plays an important role in the formation, invasion, and metastasis of osteosarcoma. Therefore, perhaps TUG1 is a potential biomarker for the prognosis of patients suffering from osteosarcoma. In this study, meta-analysis and bioinformatics were adopted to further explore the effects of TUG1 on the prognosis of patients with osteosarcoma and its potential molecular mechanism.Methods:Embase, PubMed, Sinomed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang database, and Vip Journal Integration Platform were searched from inception to May 2021. The relationship between TUG1 expression and survival outcome was estimated by hazard ratio (HRs) and 95% confidence interval (CIs). Meta-analysis was conducted on the Stata 16.0. The differential expression of TUG1 in osteosarcoma was analyzed by using UALCAN database, and the survival of TUG1 was analyzed as well. The target genes of TUG1 were predicted by RegRNA2.0 biology software, HMDD, targetscan and microTCDS, and TUG1-micoRNAs-mRNAs regulatory network was constructed. The predicted target genes obtained GeneOntology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signal transduction pathway enrichment analysis using FunRich platform.Results:The results of this meta-analysis would be submitted to peer-reviewed journals for publication.Conclusion:This study will provide evidence-based medical evidence for the relationship between TUG1 and the prognosis of osteosarcoma. Furthermore, bioinformatics analysis will provide ideas for the exploration on osteosarcoma mechanism.Ethics and dissemination:The private information from individuals will not be published. This systematic review also should not damage participants’ rights. Ethical approval is not available. The results will be published in a peer-reviewed journal or disseminated in relevant conferences.OSF registration number:DOI 10.17605/OSF.IO/CW4BF.     

消化道肿瘤患者外周血癌胚抗原mRNA水平监测与患者预后的关系研究

目的动态监测消化道恶性肿瘤患者外周血癌胚抗原(CEA)mRNA表达的水平变化,分析其与患者临床分期及预后的关系。方法在治疗前,治疗后6个月及1年采用实时荧光定量逆转录聚合酶链反应(RT-PCR)检测97例初治的消化道肿瘤患者外周血CEA mRNA的水平变化。结果97例消化道恶性肿瘤患者外周血CEA mRNA的表达阳性率为73.2%,对照组未见表达;病理分期Ⅲ、Ⅳ期患者外周血CEA mRNA的阳性比率和含量都明显高于Ⅰ、Ⅱ期患者(P<0.05);不同治疗阶段患者外周血CEA mRNA水平和患者病情、治疗效果及预后密切相关。结论荧光定量RT-PCR检测消化道恶性肿瘤患者外周血CEA mRNA的表达具有敏感性、特异性,对消化道恶性肿瘤的辅助诊断、治疗方案选择、疗效判断、有无转移和预后有着重要的临床价值。